ClinicalTrials.Veeva

Menu

New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence

Chinese Academy of Medical Sciences & Peking Union Medical College logo

Chinese Academy of Medical Sciences & Peking Union Medical College

Status

Enrolling

Conditions

Ovarian Cancer

Treatments

Other: No intervention in clinical treatment

Study type

Observational

Funder types

Other

Identifiers

NCT05410028
PUMCH-OC2

Details and patient eligibility

About

In this study, mass spectrometry was used to analyze immune inflammation-related protein complexes, post-translational modified glycopeptide omics and tumor-related metabolomics in serum, respectively, in order to find potential metabolic small molecule biomarkers or marker profiles that can be used for early diagnosis of cancer recurrence.

Full description

Time cohort study: patients with confirmed ovarian epithelial cancer at different time cutoff points before treatment, after surgery, during chemotherapy, and after chemotherapy, until clinically confirmed patients relapse. At least 50 patients are expected to be enrolled.

Enrollment

1,000 estimated patients

Sex

Female

Ages

20 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Female
  • A diagnosed patient with epithelial ovarian cancer
  • Age ≤ 70

Exclusion criteria

  • Male
  • Suffering from other malignant tumors
  • Non-compliant patient
  • Age above 70

Trial contacts and locations

1

Loading...

Central trial contact

Peng Peng, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems